C-Peptide Blood Test: Normal Range, High vs Low Levels, Diabetes, Insulin Production & Laboratory Interpretation (2026)

Clinical Chemistry • Diabetes • Endocrinology • Laboratory Interpretation

Prepared by: Dr. Omar Adwan — MedLab Academy

Last Updated: September 19, 2026

Quick Laboratory Answer

C-peptide is released by pancreatic beta cells when the body produces its own insulin. Because injected insulin does not contain C-peptide, measuring C-peptide can help estimate endogenous insulin secretion. A low result may indicate reduced beta-cell insulin production, while a high result may occur with increased endogenous insulin secretion, insulin resistance, insulinoma, certain hypoglycemic states, or reduced renal clearance. C-peptide should never be interpreted alone: the simultaneous blood glucose concentration, kidney function, fasting or fed status, diabetes history, medications, and assay-specific reference interval are essential.

Official Information Box

Primary authorities reviewed: American Diabetes Association (ADA), U.S. National Library of Medicine / MedlinePlus, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and PubMed-indexed literature.

Information verified: September 19, 2026

ADA Standards of Care in Diabetes — 2026 | MedlinePlus — C-Peptide Test | NIDDK — Diabetes Classification and C-Peptide

The C-peptide blood test is one of the most useful laboratory tools for assessing how much insulin a patient's pancreas is still producing. It is particularly valuable when clinicians need to investigate endogenous insulin production, distinguish severe insulin deficiency from preserved beta-cell function, evaluate selected cases of hypoglycemia, or clarify diabetes classification.

C-peptide is produced when proinsulin is split into insulin and C-peptide inside pancreatic beta cells. Insulin and C-peptide are therefore released together. Unlike administered insulin, however, injected insulin does not contribute C-peptide to the patient's blood. This makes C-peptide especially useful when insulin concentrations alone are difficult to interpret.

Correct interpretation is more complex than simply labeling a value as high or low. A C-peptide result must be interpreted together with the patient's blood glucose at the time of collection. A low value during hypoglycemia may be physiologically appropriate, while the same value in a markedly hyperglycemic patient may suggest inadequate pancreatic insulin secretion.

For interpretation of the glucose concentration measured with C-peptide, see the MedLab Academy Blood Glucose Test Guide .

What Is C-Peptide?

C-peptide, or connecting peptide, is a peptide produced during the formation of insulin. Pancreatic beta cells initially synthesize a larger precursor molecule called proinsulin. Proinsulin contains the insulin A chain, insulin B chain, and the connecting C-peptide segment.

During insulin processing, proinsulin is cleaved to produce biologically active insulin and C-peptide. The two products are released from pancreatic beta cells in approximately equimolar amounts.

This relationship provides the basis for C-peptide testing. When the pancreas makes insulin, it normally also releases C-peptide. Therefore:

More endogenous insulin secretion generally produces more C-peptide.
Reduced pancreatic insulin production generally produces lower C-peptide.
Injected insulin does not contain C-peptide.

C-peptide also remains in the circulation longer than insulin and undergoes substantial renal metabolism and clearance. This makes kidney function an important part of C-peptide interpretation.

Why Is a C-Peptide Test Ordered?

A C-peptide test may be requested when the clinical question involves pancreatic beta-cell function or endogenous insulin production rather than simply the blood glucose concentration.

Common clinical applications include:

Estimating residual pancreatic insulin production.
Helping classify diabetes in selected patients.
Assessing severe insulin deficiency in insulin-treated patients.
Investigating unexplained or recurrent hypoglycemia.
Supporting evaluation for endogenous hyperinsulinism.
Helping assess suspected insulinoma together with glucose, insulin and other tests.
Evaluating beta-cell function after pancreatic disease or surgery.
Supporting investigation of atypical diabetes.

C-peptide is not a replacement for glucose or HbA1c when the primary purpose is diagnosing diabetes. Diabetes is diagnosed using established glucose and/or HbA1c criteria rather than the C-peptide concentration alone.

For long-term glycemic assessment, see HbA1c Blood Test: Normal Range, Diabetes & Laboratory Interpretation .

C-Peptide Normal Range

There is no single universal C-peptide reference interval that should be applied to every patient or laboratory.

Reference intervals vary according to:

Analytical platform.
Assay manufacturer.
Specimen type.
Fasting versus nonfasting collection.
Patient population.
Time since food intake.
Concurrent blood glucose concentration.
Kidney function.

As an example, MedlinePlus Medical Encyclopedia lists a general reference range of approximately 0.3–3.3 ng/mL, while emphasizing that laboratory reference ranges differ. The performing laboratory's validated interval must always take priority.

Measurement	Example / Meaning	Important Note
C-peptide	0.3–3.3 ng/mL	Example range reported by MedlinePlus; laboratory-specific intervals vary.
C-peptide	nmol/L or pmol/L	SI units are commonly used outside the United States.
Conversion	1 ng/mL ≈ 0.331 nmol/L	Approximate conversion; report using the laboratory's validated unit.

Laboratory Pearl: A C-peptide number should not be interpreted as “normal” simply because it falls within a printed reference interval. The value must be appropriate for the simultaneous glucose concentration. A C-peptide level that appears numerically acceptable may still be inappropriately low in a patient with significant hyperglycemia.

Fasting vs Random C-Peptide

C-peptide may be measured under fasting, random, or stimulated conditions depending on the clinical question.

Fasting C-Peptide

Fasting C-peptide reflects basal endogenous insulin secretion after a period without caloric intake. It may be useful when a standardized baseline measurement is desired.

A fasting result must still be interpreted with fasting glucose. A low C-peptide concentration when glucose is also low may represent an appropriate physiological response.

Random C-Peptide

Random C-peptide is obtained without a strict fasting requirement. For diabetes classification in selected insulin-treated individuals, current ADA guidance allows a random C-peptide sample collected with concurrent glucose under defined circumstances.

The timing of food intake should be documented because recent carbohydrate intake can stimulate endogenous insulin and C-peptide secretion.

Stimulated C-Peptide

Stimulated C-peptide assesses beta-cell response after a physiological or pharmacological stimulus. Depending on the clinical protocol, stimulation may involve a mixed meal or other validated approach.

Stimulated testing may provide more information about residual beta-cell reserve than a single fasting measurement, but protocols and interpretation must be standardized.

What Does High C-Peptide Mean?

A high C-peptide concentration generally indicates that the pancreas is producing substantial amounts of endogenous insulin.

Possible causes include:

Insulin resistance.
Type 2 diabetes with preserved or increased insulin secretion.
Endogenous hyperinsulinemia.
Insulinoma.
Reduced renal clearance.
Recent food intake.
Selected endocrine disorders associated with insulin resistance.
Certain medications that stimulate endogenous insulin secretion.

High C-Peptide in Type 2 Diabetes

Early or established type 2 diabetes is commonly associated with insulin resistance. Peripheral tissues become less responsive to insulin, and pancreatic beta cells may compensate by secreting more insulin. Consequently, C-peptide can be normal or elevated.

Over time, however, beta-cell function may progressively decline. Therefore a person with long-standing type 2 diabetes can eventually develop much lower C-peptide concentrations.

This demonstrates why the statement “high C-peptide equals type 2 diabetes” is too simplistic.

High C-Peptide and Kidney Dysfunction

The kidneys play an important role in C-peptide metabolism and clearance. Reduced kidney function may increase circulating C-peptide and complicate interpretation of pancreatic beta-cell activity.

Whenever C-peptide is unexpectedly high, review serum creatinine and estimated glomerular filtration rate. See: High Creatinine Levels, eGFR & Kidney Function .

BUN may provide additional renal and hydration context: BUN Blood Test & BUN/Creatinine Ratio .

What Does Low C-Peptide Mean?

A low C-peptide concentration usually indicates reduced endogenous insulin production, but interpretation depends strongly on the glucose concentration at the same time.

Possible causes include:

Type 1 diabetes with significant beta-cell destruction.
Advanced beta-cell failure in long-standing type 2 diabetes.
Pancreatic disease causing loss of endocrine function.
Previous pancreatic surgery or pancreatectomy.
Physiological suppression when blood glucose is low.
Reduced endogenous insulin secretion during exogenous insulin therapy in some circumstances.

Low C-Peptide with High Glucose

This is one of the most clinically important patterns.

If blood glucose is clearly elevated but C-peptide is very low, the pancreas is not producing the amount of insulin that would normally be expected in response to hyperglycemia.

This pattern may support significant insulin deficiency when interpreted with the clinical history, diabetes-associated autoantibodies and other relevant data.

Low C-Peptide with Low Glucose

Low C-peptide during hypoglycemia may be completely appropriate because pancreatic insulin secretion should normally be suppressed when blood glucose falls.

Therefore the laboratory should not interpret C-peptide without knowing the simultaneous glucose result.

C-Peptide in Type 1 Diabetes

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, eventually producing severe endogenous insulin deficiency.

C-peptide concentrations may therefore become very low or undetectable as beta-cell function declines. However, some patients retain measurable C-peptide for a period after diagnosis.

A detectable C-peptide result does not automatically exclude type 1 diabetes, particularly early in the disease or when residual beta-cell function remains.

Classification should integrate:

Age and presentation.
History of ketosis or ketoacidosis.
Insulin requirement.
Islet autoantibodies.
C-peptide.
Concurrent glucose.
Family history.
Clinical phenotype.

C-Peptide in Type 2 Diabetes

People with type 2 diabetes often retain endogenous insulin secretion. During insulin resistance, pancreatic beta cells may initially increase insulin output to compensate.

C-peptide may therefore be:

Normal.
High.
Or progressively lower as beta-cell function declines.

Disease duration matters. A patient with long-standing insulin-treated type 2 diabetes may have much less endogenous insulin production than a newly diagnosed patient.

ADA 2026 C-Peptide Interpretation for Diabetes Classification

The American Diabetes Association Standards of Care in Diabetes—2026 provide specific guidance for C-peptide testing in the context of diabetes classification.

In the ADA classification algorithm for insulin-treated patients, a random C-peptide sample obtained with a simultaneous glucose result can be used in place of formal stimulation testing in appropriate circumstances.

Important values discussed in the ADA 2026 classification context include:

C-Peptide	ADA 2026 Classification Context
≥600 pmol/L (≥1.8 ng/mL)	Indicates substantial endogenous insulin secretion in the specific diabetes-classification context described by ADA.
200–600 pmol/L (0.6–1.8 ng/mL)	May occur with type 1 diabetes or monogenic diabetes, but can also occur in insulin-treated type 2 diabetes, particularly after long disease duration.
Very low, e.g. <80 pmol/L (<0.24 ng/mL)	Represents marked insulin deficiency in the appropriate clinical setting.

Important: These ADA values are used in a specific diabetes-classification pathway and should not be confused with a universal laboratory reference interval. The simultaneous glucose result, fasting status, insulin use, clinical presentation and laboratory method remain essential.

ADA 2026 also cautions against relying on C-peptide testing immediately after a hyperglycemic emergency. Clinical timing matters because acute metabolic instability can complicate interpretation.

C-Peptide in Hypoglycemia

One of the most useful applications of C-peptide is evaluation of hypoglycemia, particularly when the clinician needs to determine whether excessive circulating insulin is being produced inside the body or introduced from outside.

Ideally, insulin, C-peptide and other relevant tests are interpreted using a specimen obtained while the plasma glucose is demonstrably low.

Low Glucose + High Insulin + High C-Peptide

This pattern suggests endogenous insulin secretion.

Possible considerations include:

Insulinoma.
Other forms of endogenous hyperinsulinemia.
Insulin-secretagogue medication exposure.

Because sulfonylureas and related medications can stimulate pancreatic insulin secretion, a drug screen may be necessary in unexplained hyperinsulinemic hypoglycemia.

Low Glucose + High Insulin + Low C-Peptide

This pattern can suggest exogenous insulin exposure because pharmaceutical insulin raises the measured insulin concentration without adding C-peptide.

Interpretation requires caution because insulin immunoassays differ in their ability to detect individual insulin analogues.

Low Glucose + Low Insulin + Low C-Peptide

This suggests that insulin-mediated hypoglycemia is less likely, and other causes of low glucose should be investigated according to the clinical presentation.

C-Peptide and Insulinoma

Insulinoma is a pancreatic neuroendocrine tumor that can produce inappropriate insulin secretion. A C-peptide test may form part of the biochemical investigation when endogenous hyperinsulinemic hypoglycemia is suspected.

C-peptide alone cannot diagnose insulinoma.

The biochemical interpretation may include:

Plasma glucose.
Insulin.
C-peptide.
Proinsulin.
Beta-hydroxybutyrate.
Screening for insulin-secretagogue drugs when clinically appropriate.

Why Kidney Function Matters

C-peptide is substantially cleared and metabolized by the kidneys. Declining renal function may therefore increase circulating C-peptide concentrations independently of pancreatic insulin secretion.

This can create an important interpretation problem: a high C-peptide concentration in a patient with chronic kidney disease does not necessarily mean that beta-cell insulin output is proportionally high.

Review:

Creatinine.
eGFR.
BUN.
Previous renal results.
Clinical evidence of acute or chronic kidney dysfunction.

For a broader assessment of renal testing, see the Complete Urinalysis Guide .

C-Peptide vs Insulin Test

Feature	C-Peptide	Insulin
Produced with endogenous insulin	Yes	Yes
Present in injected insulin	No	Yes — depending on therapy and assay detection
Useful for endogenous insulin production	Very useful	More difficult in insulin-treated patients
Affected by kidney function	Yes	Metabolism differs substantially

C-Peptide vs HbA1c

C-peptide and HbA1c answer completely different laboratory questions.

Test	Main Question
C-Peptide	How much endogenous insulin is the pancreas producing?
HbA1c	What has average glycemic exposure been over recent months?
Blood Glucose	What is the glucose concentration at the time of measurement?

None of these tests should be considered interchangeable.

Specimen Requirements

C-peptide is commonly measured in serum or plasma, depending on the analytical system. Laboratories must follow the specimen requirements specified by their validated method and manufacturer.

Important pre-analytical considerations include:

Correct patient identification.
Correct specimen type.
Documented fasting or fed status when relevant.
Collection of simultaneous glucose when clinically required.
Appropriate centrifugation.
Correct storage temperature.
Appropriate transport conditions.
Avoidance of unacceptable sample deterioration.
Documentation of medications and supplements where clinically relevant.

Pre-Analytical Factors That Can Affect Interpretation

Even a perfectly functioning analyzer cannot compensate for poor pre-analytical information.

Recent Food Intake

Eating increases glucose and stimulates endogenous insulin secretion, which can increase C-peptide. A fed sample therefore should not automatically be compared with a fasting reference expectation.

Concurrent Hypoglycemia

Low glucose normally suppresses insulin and C-peptide secretion. A low C-peptide result may therefore be physiological rather than pathological.

Hyperglycemia

Hyperglycemia should normally stimulate endogenous insulin secretion when beta-cell function is preserved. A very low C-peptide in marked hyperglycemia carries a very different implication from the same C-peptide concentration during hypoglycemia.

Renal Dysfunction

Reduced renal clearance can increase C-peptide concentrations and must be considered before concluding that insulin secretion is excessive.

Acute Metabolic Emergencies

Acute diabetic metabolic emergencies may temporarily complicate assessment of stable beta-cell function. Testing should follow current clinical guidance and the purpose for which the result is being requested.

How Is C-Peptide Measured in the Laboratory?

Most routine clinical laboratories measure C-peptide using immunochemical techniques on automated chemistry or immunoassay analyzers.

Depending on the platform, methods may include:

Chemiluminescent immunoassay.
Electrochemiluminescent immunoassay.
Other validated immunometric techniques.

Results from different assays may not be completely interchangeable. Laboratories should use manufacturer-specific calibration, QC procedures, measuring intervals and reference information.

Analytical Interferences

Immunoassays may be vulnerable to analytical interference. The exact susceptibility varies by manufacturer and assay design.

Potential issues can include:

Heterophile antibodies.
Human anti-animal antibodies.
Method-specific cross-reactivity.
Biotin interference in susceptible assay designs.
Extremely high analyte concentrations in certain immunoassays.
Sample integrity problems.

Important Laboratory Principle: Do not assume that every C-peptide assay is affected by biotin in the same way. Interference is method-specific. Review the current manufacturer package insert before applying a biotin-related recommendation to a particular analyzer.

Quality Control for C-Peptide Testing

C-peptide results can influence important clinical decisions regarding insulin deficiency, diabetes classification and hypoglycemia investigation. Analytical quality must therefore be verified before patient results are released.

The laboratory should monitor:

Internal quality control at appropriate concentration levels.
Calibration status.
Reagent lot changes.
Control lot changes.
Analyzer maintenance.
Shifts and trends.
External quality assessment or proficiency testing where available.
Method comparison after major analytical changes when required.

For complete QC interpretation, see: Internal Quality Control, Westgard Rules & Levey–Jennings Charts .

Laboratories should also monitor system-wide quality measures. See: Laboratory Quality Indicators, KPIs & ISO 15189 .

C-Peptide Interpretation Patterns

Glucose	C-Peptide	Possible Interpretation
High	High	Preserved endogenous secretion; insulin resistance may be present.
High	Very low	Significant endogenous insulin deficiency should be considered.
Low	Low	May represent normal physiological suppression.
Low	Inappropriately high	Endogenous hyperinsulinemic hypoglycemia or insulin-secretagogue exposure should be considered.